Key clinical point: Romosozumab’s efficacy was not affected by renal insufficiency in patients with osteoporosis.
Major finding: Bone mineral density increased in all romosozumab groups regardless of estimated glomerular filtration rate (eGFR), and the risk of new vertebral fractures was decreased in all eGFR subgroups and did not appear to be affected by eGFR level.
Study details: A post hoc analysis of 7,180 postmenopausal women at various stages of renal insufficiency in the FRAME study who received romosozumab or placebo for 12 months.
Disclosures: This study was sponsored in part by Amgen, Astellas, and UCB Pharma. Dr. Miller reported receiving grants from Alexion, Amgen, Radius, Regeneron, UCB, and Ultragenyx. Amgen and UCB assisted in and provided financial assistance for the preparation of Dr. Miller’s presentation.
Miller P et al. ASBMR 2019. Abstract 1085.